Fisetin in Mild Alzheimer's Disease

Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age60+
SponsorSunnybrook Health Sciences Centre

About this trial

This pilot study will evaluate the safety and tolerability of the natural health product, fisetin, in older adults with mild cognitive impairment or mild Alzheimer's disease dementia.

Eligibility criteria

Qualifiers

Mild cognitive impairment due to Alzheimer's disease OR mild Alzheimer Dementia

Moca score of 11 or higher

Stable psychotropics and cognitive enhancing medications

Disqualifiers

Known hypersensitivity or allergy to fisetin

Presence of any medical condition, or abnormal routine blood test, that the investigator believes would put the subject at risk or would preclude the patient from completing all aspects of the trial

Unstable medical disorders

Ongoing treatment for active infection with antibiotics/antifungals

Trial design

Treatments tested in this trial

  • Fisetin

Treatment groups

5 Participants
are divided into 1 treatment group

Sponsors and collaborators

Sunnybrook Health Sciences Centre

Lead sponsor

Sunnybrook Research Institute

Collaborator